In mouse models, a novel hepatokine called SDC4 responds to exercise and reduces fatty acid uptake and liver steatosis, offering potential insights into novel targets for NAFLD treatment by elucidating the proteome alterations in hepatocytes due to exercise [33]. This evidence concerns the gene SDC4 and metabolic dysfunction-associated steatotic liver disease.